IRB Approval in Regenerative Medicine: What It Means (and Doesn't Mean) for Your Supplier

As the regenerative medicine market has grown, clinicians have needed a fast, reliable way to separate suppliers operating within recognized quality and ethical standards from those that aren't. Earlier articles in this series covered cell culture standards and the basic FDA and state regulatory framework. This one looks at a specific credential that comes up often when evaluating a supplier: Institutional Review Board, or IRB, approval, what it actually documents, and just as importantly, what it doesn't.

What is an IRB, exactly?

An Institutional Review Board is an independent committee formally designated to review, approve, and monitor biomedical research involving human subjects. Under FDA regulations, an IRB has the authority to approve, require changes to, or reject a proposed research protocol. Its core purpose is to make sure the rights, safety, and privacy of research participants are protected, both before a study starts and on an ongoing basis as it runs.

IRB oversight is relevant to stem cell and exosome products for three reasons:

It documents independent ethical review. IRB approval means a third party, separate from the company or clinic running the study, has reviewed the clinical protocol, including the informed consent process, the risk-benefit analysis, and the plan for monitoring participant safety.

It sits within a recognized regulatory pathway. IRB approval is not the same thing as FDA approval, and it doesn't substitute for it. What it does is place a study inside a structured, federally recognized process for human subjects research, which is a meaningfully different position than operating with no formal oversight at all.

It reflects a real investment from the supplier. Preparing a protocol for IRB review takes time, documentation, and scientific justification. A supplier that has gone through this process has taken on real accountability that not every company in this market chooses to take on.

Florida's stem cell law and IRB-relevant requirements

Florida Senate Bill 1768 (codified as Sections 458.3245 and 459.0127 of the Florida Statutes) took effect July 1, 2025. It allows licensed MDs and DOs to administer stem cell therapies that are not FDA-approved, within specific limits. The key requirements are:

• Scope of use. Treatments are limited to orthopedic conditions, wound care, or pain management.
• Sourcing restrictions. The law prohibits stem cells derived from aborted fetal tissue, a third-degree felony under the statute, and points toward ethically sourced alternatives such as adult stem cells and umbilical cord blood.
• Informed consent. Patients must receive a clear, written explanation that the therapy is not FDA-approved, along with its potential benefits, risks, and alternatives.
• Manufacturing standards. Stem cells must be retrieved, manufactured, and stored in a facility that is registered with the FDA. The statute specifically requires compliance with applicable current Good Manufacturing Practices under 21 CFR Part 1271.
• Accreditation. The facility must hold accreditation from a recognized body, such as AATB, AABB, or NMDP.

A regulatory clarification worth flagging: 21 CFR Part 1271 is generally described as the framework for Current Good Tissue Practice (cGTP), the standard specific to human cells and tissue-based products, rather than cGMP, which is the standard for drugs and biologics. Florida's statute uses "current good manufacturing practices" language while citing 21 CFR 1271, which means the practical requirement is compliance with the tissue-specific standards under that part of the federal code. If you're evaluating a supplier's paperwork, the useful question is which specific FDA framework their facility registration and quality documentation actually cite, not just which acronym is printed on their marketing materials.

None of this constitutes an IRB approval on its own. But together, these requirements create the kind of documented, ethically sourced foundation that an IRB-approved clinical protocol would typically be built on top of.

A documented example: RegenOMedix's IRB approval announcement

On February 6, 2026, RegenOMedix announced that it had received IRB approval for the clinical use of its Ascellos stem cells and exosome products in the areas of pain management, orthopedics, and wound healing, according to the company's own public announcement. The company states that the products used in the study are intended to comply with Florida's stem cell law.

Based on that announcement, the reported elements of the program include:

A defined clinical protocol. The IRB approval covers a specific study protocol, meaning participating physicians work within an established framework for data collection and outcome tracking, rather than administering treatment without a structured research process.

A dedicated data-tracking system. The company states it uses a portal, ClinicalStudyResearch.com, for structured patient tracking and outcome monitoring within the study.

Clearly stated regulatory limits. According to the announcement, the IRB approval covers oversight of the clinical study, protocol adherence, and data collection. It does not constitute FDA approval, and it does not authorize marketing the product for general therapeutic use outside the study. This distinction is stated directly in the company's own materials and is worth repeating to any patient or colleague who might otherwise conflate "IRB-approved" with "FDA-approved."

A defined clinical scope. The study is described as focused on joint and musculoskeletal pain, orthopedic injuries, and chronic or complex wound care, which the announcement states falls within the scope Florida SB 1768 authorizes.

This example is included to illustrate what a documented IRB-approval announcement looks like in practice, based on the supplier's own public statements. It is not an independent verification of the study's outcomes or of the product's safety or effectiveness, and it should not be read as one. Anyone evaluating this or any other IRB-approved program should request the underlying protocol and documentation directly rather than relying on a company's summary of it.

Why documented compliance should be non-negotiable

When evaluating a supplier, licensed clinics should ask for documentation of:

• IRB approval for the specific intended use of the product, where one exists
• FDA tissue establishment registration
• Compliance with the applicable regulatory framework (cGTP under 21 CFR Part 1271, and cGMP where it separately applies) for the specific product in question
• AATB accreditation or an equivalent recognized accreditation
• Lot-specific Certificates of Analysis covering sterility, viability, and potency
• Transparent sourcing and chain-of-custody documentation

A supplier that cannot produce these documents on request should be treated with real caution, regardless of how the product is marketed.

If you're considering participating in an IRB-approved study

Licensed physicians interested in participating in an IRB-approved regenerative medicine study, such as the one described above, should contact the sponsoring organization directly to request the full protocol, the informed consent materials, and the IRB approval documentation itself, rather than relying on a summary. Participating in a properly documented study is one legitimate way to contribute to the evidence base in this field under structured oversight.

Frequently Asked Questions

Does IRB approval mean a product is FDA approved? No. IRB approval and FDA approval are separate processes that answer different questions. An IRB approves the ethics and safety oversight of a specific research protocol. FDA approval is a separate determination that a product has been shown to be safe and effective for a specific use, based on a full review of clinical data. A product can have IRB approval for a study without ever receiving FDA approval, and that is the current status of exosome products generally: there are no FDA-approved exosome products for any therapeutic use in the United States.

Is IRB approval required for every stem cell or exosome product? IRB approval is specifically required for research involving human subjects, including studies intended to generate data that could support a future FDA application. Not every use of a legally sourced product is necessarily part of a formal research study, but a documented IRB-approved protocol is a meaningful positive signal when a supplier is running one.

What should I ask for if a supplier says its product has IRB approval? Ask to see the actual approval documentation and the study protocol, not just a marketing summary. Confirm what specific use the approval covers, what clinical outcomes are being tracked, and how patient data is being collected and monitored.

How does IRB approval relate to Florida's SB 1768? SB 1768 sets sourcing, manufacturing, accreditation, and consent requirements for physicians using non-FDA-approved stem cell therapies in Florida. It does not itself require IRB approval for every use permitted under the law, but a supplier running a properly IRB-approved study on top of SB 1768-compliant sourcing is demonstrating a more complete compliance posture than sourcing requirements alone would require.

Can physicians outside Florida participate in an IRB-approved study? That depends on the specific study's protocol and the sponsoring organization's requirements, which is a question to direct to the study sponsor rather than assume one way or the other.

Key Takeaways

• An IRB is an independent committee that reviews and monitors human-subjects research to protect participant safety, rights, and privacy.
• IRB approval is not FDA approval and does not authorize marketing a product for general therapeutic use. Those are two separate regulatory questions.
• Florida's SB 1768 sets specific sourcing, manufacturing, accreditation, and consent standards for physicians using non-FDA-approved stem cell therapies, and cites 21 CFR Part 1271, the framework generally associated with cGTP for tissue products.
• A documented IRB approval, paired with FDA facility registration, accreditation, and lot-specific testing, is a meaningful positive signal about a supplier's compliance posture, but it should always be verified directly rather than taken from marketing materials alone.
• There are currently no FDA-approved exosome products for any therapeutic use, IRB-approved study or not.

References

1. "Institutional Review Boards (IRBs) and Protection of Human Subjects in Clinical Trials," U.S. Food and Drug Administration (FDA). Available: https://www.fda.gov/about-fda/cder-offices-and-divisions/institutional-review-boards-irbs-and-protection-human-subjects-clinical-trials
2. "Institutional Review Boards Frequently Asked Questions," U.S. Food and Drug Administration (FDA). Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/institutional-review-boards-frequently-asked-questions
3. "The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards?" PMC, 2018. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC6028208/
4. "CS/CS/SB 1768 (2025), Enrolled Bill Text," The Florida Senate, 2025. Available: https://www.flsenate.gov/Session/Bill/2025/1768/BillText/er/HTML
5. "New Florida Law Attempts to Provide Leeway for Certain Stem Cell Treatments," Holland & Knight, Aug. 2025. Available: https://www.hklaw.com/en/insights/publications/2025/08/new-florida-law-attempts-to-provide-leeway-for-certain-stem-cell
6. "Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)," U.S. Food and Drug Administration (FDA). Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-tissue-practice-cgtp-and-additional-requirements-manufacturers-human-cells-tissues-and
7. "AATB Accreditation," American Association of Tissue Banks (AATB). Available: https://www.aatb.org/accreditation
8. "RegenOMedix Receives IRB Approval for Clinical Use of Ascellos Stem Cells and Therapeutic Exosomes," RegenOMedix, Feb. 2026. Available: https://regenomedix.com/regenomedix-receives-irb-approval/
9. "Public Safety Alert Due to Marketing of Unapproved Stem Cell and Exosome Products," U.S. Food and Drug Administration (FDA). Available: https://www.fda.gov/safety/medical-product-safety-information/public-safety-alert-due-marketing-unapproved-stem-cell-and-exosome-products

This article is intended for general educational and informational purposes only. There are currently no FDA-approved exosome products for any therapeutic indication in the United States. Nothing here constitutes legal advice or a therapeutic claim. Healthcare practitioners should consult qualified legal counsel and regulatory experts for guidance specific to their own practice.